Symbol="TARS"
AssetType="Common Stock"
Name="Tarsus PharmaceuticalsÂ Inc"
Description="Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California."
CIK="1819790"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="15440 LAGUNA CANYON ROAD, IRVINE, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="524548000"
EBITDA="-67755000"
PERatio="None"
PEGRatio="None"
BookValue="6.47"
DividendPerShare="0"
DividendYield="0"
EPS="-1.77"
RevenuePerShareTTM="1.063"
ProfitMargin="-2.35"
OperatingMarginTTM="-2.453"
ReturnOnAssetsTTM="-0.217"
ReturnOnEquityTTM="-0.405"
RevenueTTM="27777000"
GrossProfitTTM="-17763000"
DilutedEPSTTM="-1.77"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="3.638"
AnalystTargetPrice="53.13"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="24.75"
PriceToBookRatio="2.038"
EVToRevenue="12.78"
EVToEBITDA="-3.446"
Beta="0.652"
num_52WeekHigh="25.25"
num_52WeekLow="11.33"
num_50DayMovingAverage="18.4"
num_200DayMovingAverage="16.05"
SharesOutstanding="26803700"
DividendDate="None"
ExDividendDate="None"
symbol="TARS"
open="20.14"
high="20.44"
low="18.12"
price="18.27"
volume="1209604.00"
latest_trading_day="2023-08-01"
previous_close="22.01"
change="-3.74"
change_percent="-16.9923%"
aroon_positive_momentum_days="61"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="61"
Volume_recent_avg="255214"
Change_recent_avg="0.04"
Delta_recent_avg="0.91"
Variance_recent_avg="0.45"
Change_ratio_recent_avg="0.14"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="61"
Aroon_momentum_negative="39"
image_negative_thumbnail_id_1="503"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0102.jpeg"
image_negative_thumbnail_id_2="1121"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0154.jpeg"
image_neutral_thumbnail_id_1="556"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0043.jpeg"
image_neutral_thumbnail_id_2="575"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0024.jpeg"
image_positive_thumbnail_id_1="620"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0088.jpeg"
image_positive_thumbnail_id_2="958"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0120.jpeg"
image_professor_thumbnail_id_1="1167"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
